Research article summary (published 30 Dec 2005):

Anticipating a Vioxx defense strategy: will corporate honesty be enough?

Full Abstract

No abstract is available for this article. See 'Journal and Publication Information' further down the page for details that may assist you in locating this article in electronic or hard copy media. The 'Related articles' section also further down the page, where available, may show links to abstracts of articles covering similar topics.

Learn Faster Today      Improve your study skills

Author information

Author/s: Willis, Kirk D (KD);

Affiliation: Godwin Pappas Langley Ronquillo, LLP, Dallas, Texas USA. kwillis(-atsign-)godwinpappas.com

Journal and publication information

Publication Type: Journal Article

Journal: Tort trial & insurance practice law journal (Tort Trial Insur Pract Law J), published in United States. (Language: eng)

Reference: 2006-; vol 41 (issue 4) : pp 1163-78

Dates: Created 2006/11/08; Completed 2006/11/29;

PMID: 17091567, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Anti-Inflammatory Agents, Non-Steroidal - adverse effects Consumer Product Safety Drug Industry - legislation & jurisprudence Drug and Narcotic Control - legislation & jurisprudence Ethics, Business

Humans Lactones - adverse effects Sulfones - adverse effects United States United States Food and Drug Administration

Associated Chemicals: Anti-Inflammatory Agents, Non-Steroidal (0) ; Lactones (0) ; Sulfones (0)

Related articles

These are the highest related articles currently in the database:

• Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? 13 Nov 2004
• Balancing risks and benefits in pain medicine: wither Vioxx. 29 Nov 2004
• Lessons to be learned from the Vioxx debacle. 30 Dec 2004
• National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. 22 Jan 2005
• [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall] 30 Dec 2004
• Painkiller in the dock. 26 Jul 2005
• The pain game. 24 Jul 2007
• Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. 7 Aug 2004
• How to avoid another 'Vioxx'. 30 Dec 2004
• Drug safety. FDA panel urges caution on many anti-inflammatory drugs. 23 Feb 2005

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.